JPH10512583A - アルコール嗜癖の治療のための製薬学的組成物 - Google Patents
アルコール嗜癖の治療のための製薬学的組成物Info
- Publication number
- JPH10512583A JPH10512583A JP8533745A JP53374596A JPH10512583A JP H10512583 A JPH10512583 A JP H10512583A JP 8533745 A JP8533745 A JP 8533745A JP 53374596 A JP53374596 A JP 53374596A JP H10512583 A JPH10512583 A JP H10512583A
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- water
- extract
- alcohol
- tandinone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000007848 Alcoholism Diseases 0.000 title claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 6
- 239000000284 extract Substances 0.000 claims abstract description 33
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 10
- 241001072909 Salvia Species 0.000 claims description 9
- 235000017276 Salvia Nutrition 0.000 claims description 9
- 241000612118 Samolus valerandi Species 0.000 claims description 6
- 244000132619 red sage Species 0.000 claims description 5
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 claims description 4
- 239000012074 organic phase Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 2
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract description 2
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
- 201000007930 alcohol dependence Diseases 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- HYXITZLLTYIPOF-UHFFFAOYSA-N 1,6,6-trimethyl-8,9-dihydro-7H-naphtho[1,2-g]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- FEFAIBOZOKSLJR-UHFFFAOYSA-N Miltirone Chemical compound C1CCC(C)(C)C=2C1=C1C(=O)C(=O)C(C(C)C)=CC1=CC=2 FEFAIBOZOKSLJR-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 229940084657 Benzodiazepine receptor inverse agonist Drugs 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000755 benzodiazepine receptor inverse stimulating agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Addiction (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 5から30% w/wまでのタンジノン II A及び0.5から3% w/w までのミルティロンを含むことを特徴とする、タンジン(Salvia mil tiorrhyza Bunge)の根の親油性抽出物。 2. 15から25% w/wまでのタンジノン II Aを含んでいる請求の範囲 1に記載の抽出物。 3. 0.8から2%までのミルティロンを含んでいる請求の範囲1または2に 記載の抽出物。 4. タンジン(Salvia miltiorrhyza)の根のアセトンで の抽出、それに続く濃縮、濃縮物の水及び水と混和しない溶媒での処理、水での 洗浄によるアセトンの除去、並びに有機相の濃縮を含んでなる、請求の範囲1− 3の抽出物の調製方法。 5. タンジン(Salvia miltiorrhyza)の根のアセトンで の抽出、それに続く濃縮、濃縮物の水及び水と混和しない溶媒での処理、水での 洗浄によるアセトンの除去、並びに有機相の濃縮により得ることのできるタンジ ン(Salvia miltiorrhyza Bunge)の親油性抽出物。 6. 適当なキャリヤーと混合して請求の範囲1−3または5に記載の抽出物を 含んでいる経口の製薬学的組成物。 7. カプセルまたは錠剤の形態の請求の範囲6に記載の組成物。 8. アルコール嗜癖の治療用薬剤の調製のための請求の範囲1−3または5に 記載の抽出物の使用。 9. アルコール嗜癖の治療用薬剤の調製のためのタンジノン II Aの 使用。 10. アルコール嗜癖の治療用薬剤の調製のためのミルティロンの使用。 11. 適当なキャリヤーと混合してタンジノン II A及び/またはミルティロ ンを有効成分として含んでいる経口の製薬学的組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI950958A IT1274481B (it) | 1995-05-12 | 1995-05-12 | Composizioni farmaceutiche per il trattamento della alcol-dipendenza |
IT95A000958 | 1995-05-12 | ||
PCT/EP1996/001916 WO1996035441A1 (en) | 1995-05-12 | 1996-05-08 | Pharmaceutical compositions for the treatment of alcohol addiction |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10512583A true JPH10512583A (ja) | 1998-12-02 |
JP2955370B2 JP2955370B2 (ja) | 1999-10-04 |
Family
ID=11371582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8533745A Expired - Fee Related JP2955370B2 (ja) | 1995-05-12 | 1996-05-08 | アルコール嗜癖の治療のための製薬学的組成物 |
Country Status (17)
Country | Link |
---|---|
US (1) | US5904923A (ja) |
EP (1) | EP0824356B1 (ja) |
JP (1) | JP2955370B2 (ja) |
KR (1) | KR100290029B1 (ja) |
CN (1) | CN1066336C (ja) |
AT (1) | ATE221384T1 (ja) |
AU (1) | AU695010B2 (ja) |
CA (1) | CA2220703C (ja) |
DE (1) | DE69622704T2 (ja) |
DK (1) | DK0824356T3 (ja) |
ES (1) | ES2180783T3 (ja) |
HK (1) | HK1009096A1 (ja) |
IT (1) | IT1274481B (ja) |
NO (1) | NO318659B1 (ja) |
PT (1) | PT824356E (ja) |
RU (1) | RU2153345C2 (ja) |
WO (1) | WO1996035441A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1001797E (pt) | 1997-07-30 | 2005-08-31 | Indena Spa | Extracto de soja, processo para a sua preparacao e composicao farmaceutica |
US5968746A (en) | 1997-11-26 | 1999-10-19 | Schneider; David R. | Method and apparatus for preserving human saliva for testing |
AU2001286409A1 (en) * | 2000-08-03 | 2002-02-18 | Hong Kong University Of Science And Technology | N-methyl-d-aspartate receptor antagonists |
CN1304723A (zh) * | 2001-01-16 | 2001-07-25 | 中山大学 | 含二氢呋喃环结构的丹参酮类化合物用于治疗肝性脑病的药物 |
US6852342B2 (en) | 2002-03-26 | 2005-02-08 | Avoca, Inc. | Compounds for altering food intake in humans |
WO2004058245A1 (fr) * | 2002-12-31 | 2004-07-15 | Zhongshan Univertsity | Utilisation de la tanshinone iia dans la prophylaxie ou le traitement de l'atherosclerose |
US9827314B2 (en) * | 2003-12-08 | 2017-11-28 | Mars, Incorporated | Edible compositions which are adapted for use by a companion animal |
AU2006235318A1 (en) * | 2005-04-07 | 2006-10-19 | Hythiam, Inc. | Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence |
GB201312205D0 (en) * | 2013-07-08 | 2013-08-21 | Univ Leuven Kath | Anticonvulsant activity of dan shen extracting compounds |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1239281B (it) * | 1989-10-27 | 1993-10-19 | Indena Spa | Composizioni per la riduzione dei depositi di grasso superfluo a base di principi attivi di origine vegetale ad attivita' agonista dell'adenilato ciclasi o/e ad attivita' antifosfodiesterasica |
US5204369A (en) * | 1991-07-01 | 1993-04-20 | The Endowment For Research In Human Biology | Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse |
-
1995
- 1995-05-12 IT ITMI950958A patent/IT1274481B/it active IP Right Grant
-
1996
- 1996-05-08 JP JP8533745A patent/JP2955370B2/ja not_active Expired - Fee Related
- 1996-05-08 AU AU58153/96A patent/AU695010B2/en not_active Ceased
- 1996-05-08 AT AT96919706T patent/ATE221384T1/de active
- 1996-05-08 CN CN96193877A patent/CN1066336C/zh not_active Expired - Fee Related
- 1996-05-08 KR KR1019970708033A patent/KR100290029B1/ko not_active IP Right Cessation
- 1996-05-08 PT PT96919706T patent/PT824356E/pt unknown
- 1996-05-08 DK DK96919706T patent/DK0824356T3/da active
- 1996-05-08 CA CA002220703A patent/CA2220703C/en not_active Expired - Fee Related
- 1996-05-08 US US08/945,986 patent/US5904923A/en not_active Expired - Lifetime
- 1996-05-08 WO PCT/EP1996/001916 patent/WO1996035441A1/en active IP Right Grant
- 1996-05-08 RU RU97120507/14A patent/RU2153345C2/ru not_active IP Right Cessation
- 1996-05-08 EP EP96919706A patent/EP0824356B1/en not_active Expired - Lifetime
- 1996-05-08 DE DE69622704T patent/DE69622704T2/de not_active Expired - Lifetime
- 1996-05-08 ES ES96919706T patent/ES2180783T3/es not_active Expired - Lifetime
-
1997
- 1997-11-11 NO NO19975177A patent/NO318659B1/no not_active IP Right Cessation
-
1998
- 1998-08-21 HK HK98110082A patent/HK1009096A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP0824356A1 (en) | 1998-02-25 |
NO975177L (no) | 1997-11-11 |
NO318659B1 (no) | 2005-04-25 |
DE69622704D1 (de) | 2002-09-05 |
HK1009096A1 (en) | 1999-05-28 |
JP2955370B2 (ja) | 1999-10-04 |
CN1184429A (zh) | 1998-06-10 |
CA2220703A1 (en) | 1996-11-14 |
CA2220703C (en) | 2001-07-24 |
AU5815396A (en) | 1996-11-29 |
ATE221384T1 (de) | 2002-08-15 |
DE69622704T2 (de) | 2003-04-03 |
PT824356E (pt) | 2002-12-31 |
CN1066336C (zh) | 2001-05-30 |
DK0824356T3 (da) | 2002-11-25 |
AU695010B2 (en) | 1998-08-06 |
EP0824356B1 (en) | 2002-07-31 |
ITMI950958A1 (it) | 1996-11-12 |
RU2153345C2 (ru) | 2000-07-27 |
WO1996035441A1 (en) | 1996-11-14 |
IT1274481B (it) | 1997-07-17 |
NO975177D0 (no) | 1997-11-11 |
US5904923A (en) | 1999-05-18 |
ITMI950958A0 (it) | 1995-05-12 |
KR100290029B1 (ko) | 2001-05-15 |
KR19990014692A (ko) | 1999-02-25 |
ES2180783T3 (es) | 2003-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3570989B2 (ja) | 大豆抽出物、その調製方法および医薬組成物 | |
JP2985133B2 (ja) | 人体中の沈着脂肪を処理するための組成物 | |
JP2002187848A (ja) | 茶のポリフェノール画分、その使用、及びそれを含有する処方物 | |
WO2006002096A2 (en) | Low doses of l-citrulline for treating diseases | |
US20230087359A1 (en) | Cannabinoid compositions and methods of use thereof | |
KR101704918B1 (ko) | 혼합 생약 추출물을 유효성분으로 포함하는 파킨슨병의 예방 또는 치료용 약학적 조성물 | |
EP1652520A2 (en) | Formulations useful in the treatment of male and female impotence | |
JP2003511476A (ja) | 赤色ブドウ樹葉の抽出物を用いる慢性静脈不全の治療方法 | |
JPH10512583A (ja) | アルコール嗜癖の治療のための製薬学的組成物 | |
CN100522193C (zh) | 构树果色素的用途 | |
JP2007517785A (ja) | 慢性静脈不全の治療のための赤ブドウの葉の水性抽出物及び利尿剤を含む組成物 | |
JP3091962B2 (ja) | テストステロン−5α−レダクターゼ阻害剤 | |
KR101822834B1 (ko) | 갱년기 증상 완화용 조성물 | |
WO2009076869A1 (zh) | 高纯度丹酚酸、制备方法及应用 | |
JPH11500738A (ja) | アルコール嗜癖の治療のための薬剤の製造におけるフォルスコリンまたはそれを含んでいる抽出物の使用 | |
CN111374970A (zh) | 一种具有抗结肠炎活性的组合物及其应用 | |
KR100672036B1 (ko) | 인동 추출물을 함유한 천식 치료제 | |
WO2001039785A1 (fr) | Formulation contenant un extrait de feuille de cacahouete et son procede de preparation | |
JPH0474333B2 (ja) | ||
JP2000119187A (ja) | 抑うつ気分の予防または改善用組成物 | |
EP1226827B1 (en) | Pharmaceutical composition comprising rutin and lespedeza capitata extract for treating oedema | |
KR20040050396A (ko) | 천궁을 이용한 일산화질소 생성제 조성물 및 이를 이용한약품 조성물 | |
WO2006005219A1 (fr) | Composition pharmaceutique pour traiter la depression, et procede pour la preparer | |
US20130079295A1 (en) | Treatment of cartilage resorption | |
KR20030056579A (ko) | 알레르기성 질환의 예방 및 치료용 조성물 및 그 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070716 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080716 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090716 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090716 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100716 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110716 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120716 Year of fee payment: 13 |
|
LAPS | Cancellation because of no payment of annual fees |